How Long Can You Live With Aortic Regurgitation?

People with chronic aortic regurgitation often live for decades, especially when the condition is caught early and monitored. A landmark study tracking asymptomatic patients with preserved heart function found that roughly six in ten remained symptom-free with a normal pumping ability at eleven years. But the timeline varies enormously depending on the severity of the leak, how well the heart adapts, and whether surgery happens at the right moment. What looks like a stable condition on the surface can quietly shift toward irreversible heart damage, which makes understanding the trajectory of this disease more useful than any single life-expectancy number.

The Asymptomatic Window

Chronic aortic regurgitation is unusual among heart conditions in that it can remain completely silent for years. The classic natural-history study by Bonow and colleagues followed patients with severe regurgitation but normal heart function over more than a decade. About 58% of them stayed asymptomatic with a preserved pumping fraction at eleven years, losing ground at a rate of less than 5% per year. Two patients died suddenly during follow-up, and nineteen eventually needed surgery because symptoms appeared.¹ That study shaped how cardiologists think about the disease: as a condition with a long, deceptively quiet phase before trouble arrives.

A more recent meta-analysis pooling data from multiple studies paints a somewhat less reassuring picture. The overall death rate among asymptomatic patients with moderate or severe regurgitation was about 1.75 per 100 person-years, which is more than double what you would expect for the general population matched by age. For cohorts with an average age of 50 or older, the rate climbed to roughly 2.45 per 100 person-years, compared with about 0.59 for younger cohorts. The authors concluded that even asymptomatic moderate-to-severe aortic regurgitation carries meaningful excess mortality, pushing back against the long-held view that the condition is essentially benign until symptoms show up.²

How the Heart Adapts, and Why That Eventually Fails

When the aortic valve leaks, blood that was just pumped forward slips back into the left ventricle during each heartbeat. The ventricle responds by stretching and growing thicker to handle the extra volume. This remodeling is initially a smart adaptation: the enlarged chamber can accommodate the backflow and still push enough blood forward to meet the body’s needs.³ For years, the heart can maintain a normal pumping fraction despite the leak, which is why patients feel fine during the asymptomatic phase.

The problem is that the heart muscle eventually runs out of compensatory capacity. The stretching that once helped starts to work against itself: the wall thins relative to the chamber size, muscle fibers become less efficient, and scar tissue begins replacing healthy muscle. Once the pumping fraction drops or the ventricle dilates past certain thresholds, the damage may be only partially reversible even with surgery. This is the central tension in managing aortic regurgitation: the best time to intervene is before the patient feels sick, but the patient who feels fine is understandably reluctant to have heart surgery.

Severity and Its Effect on Survival

Not all aortic regurgitation carries equal risk. A large study examining untreated outcomes found that two-year all-cause mortality rose in a stepwise fashion with leak severity: about 7% for none-to-mild, roughly 11% for moderate, and around 15% for severe regurgitation. The hazard for death was about 2.4 times higher in severe disease compared with mild, and roughly 1.3 times higher in moderate disease. Other factors that independently worsened the outlook included a reduced pumping fraction, enlargement of the left ventricle or left atrium, atrial fibrillation, and elevated levels of a heart-stress blood marker called BNP.⁴

The underlying cause of the leak also influences the long-term picture. People born with a bicuspid aortic valve, which has two leaflets instead of the usual three, tend to develop regurgitation at a younger age and face a rising event rate as severity increases.⁵ On the other hand, younger patients generally tolerate the volume overload better and have more time in the compensated phase than older patients do, as reflected in the mortality-rate gap between younger and older cohorts noted in the meta-analysis discussed earlier.²

When Surgery Becomes the Right Call

The decision to operate hinges on a combination of symptoms, heart size, and pumping function. Current guidelines recommend surgery when symptoms develop, when the pumping fraction drops, or when the left ventricle enlarges beyond certain thresholds on imaging. The tricky part is defining those thresholds precisely enough to catch the transition from compensated to decompensated disease without intervening too early.

Research into the best imaging cutoffs has shown that using body-size-adjusted measurements can improve predictions. One study found that indexing the left ventricle’s end-systolic dimension to body surface area outperformed the traditional raw measurement: when a lower, indexed threshold was used as the trigger for surgery instead of the old fixed cutoff, the projected ten-year mortality dropped from about 38% to 24%.⁶ An earlier study found a similar story: patients whose preoperative ventricle dimensions exceeded certain body-adjusted thresholds had only about 71% survival at four years after surgery, compared with 96% for those whose hearts were smaller at the time of the operation.⁷ The lesson from both studies is the same: waiting too long before surgery lets the heart remodel past a point of no return, and the size of the heart at the time of surgery is one of the strongest predictors of how well you do afterward.

Life After Aortic Valve Surgery

For patients who undergo surgery at the right time, the outlook is encouraging. A study of patients with bicuspid aortic valves who had aortic valve surgery found that their survival at ten years was essentially identical to the general population matched for age, sex, and calendar year. Even at twelve years, relative survival was about 95% of the matched population, meaning only about 5% of deaths over that period could be attributed to the surgery or its downstream consequences.⁸

However, not everyone fares that well. Patients who come to surgery with already-weakened heart muscle do worse. A study measuring heart contractility before valve replacement found that the average annual mortality risk after surgery was about 3.2% for the full cohort. When divided by preoperative contractility, the best third had an annual risk of only 1.4%, which was statistically indistinguishable from the general population. The worst third had an annual risk of 6.4%.⁹ This reinforces the theme: timing matters enormously, and the heart’s condition when it reaches the operating table is a better predictor of long-term survival than almost any other factor.

Why Medications Have Not Changed the Story

You might wonder whether drugs that lower blood pressure or reduce the heart’s workload could slow the progression of regurgitation and delay surgery. A well-designed trial tested exactly this, randomizing patients with severe aortic regurgitation to either a calcium-channel blocker (nifedipine), an ACE inhibitor (enalapril), or no treatment, then followed them for an average of seven years. The rate of eventual valve replacement was essentially the same across all three groups: roughly 40 to 50%, with no statistically significant difference. The drugs also failed to produce meaningful differences in the size of the leak, heart size, heart mass, or pumping function.¹⁰

This result is important because it means there is no pill that can substitute for careful monitoring and well-timed surgery. Medications are still used to manage symptoms like high blood pressure or heart failure in patients who cannot undergo surgery, but they do not alter the fundamental disease trajectory. The leak itself is a mechanical problem, and a mechanical fix is ultimately what changes outcomes.

Hidden Heart Damage and Advanced Imaging

One of the more sobering discoveries in recent years is how common hidden heart damage is in aortic regurgitation patients, even those who appear to be doing well by standard measures. Cardiac MRI can detect two forms of damage: replacement fibrosis, where scar tissue has replaced dead muscle, and diffuse interstitial fibrosis, where excess connective tissue is woven between living muscle fibers. Both carry prognostic weight.

In a study of nearly 400 patients with at least moderate regurgitation, about a third had myocardial scar visible on MRI. The presence of scar more than doubled the risk of death over follow-up, even after accounting for other risk factors. Among patients with scar who then underwent valve replacement, surgery was associated with a substantially lower risk of death, suggesting that even those with hidden damage can benefit from intervention.¹¹ A separate study using both MRI and tissue samples confirmed that patients with more fibrosis had worse functional recovery after surgery and lower long-term survival.¹²

Another MRI-based marker, the indexed extracellular volume, captures the diffuse fibrosis that standard scar imaging misses. In a study of 177 patients, this marker tracked closely with regurgitation severity and was independently associated with the combined endpoint of death or valve replacement. Patients who had both a significant leak and a high indexed extracellular volume fared the worst.¹³ These findings are gradually changing how cardiologists decide when to intervene: traditional echocardiography captures heart size and pumping fraction, but MRI can reveal damage that is already under way before those numbers change.

Transcatheter Options for Patients Who Cannot Have Open Surgery

Open-heart surgery remains the standard treatment, but some patients are too frail or too high-risk for a conventional operation. Transcatheter aortic valve replacement, where a new valve is threaded through a blood vessel and deployed inside the old one, has been used successfully for aortic stenosis (a narrowed valve) for years. Applying the same technology to a leaky valve is harder because the regurgitant valve lacks the calcified scaffolding that helps anchor a replacement device.

Early results with first-generation devices reflected this difficulty: 30-day mortality was about 17%, and device success reached only around 63%. Newer, purpose-built devices have improved those numbers considerably. A meta-analysis found that devices designed specifically for regurgitation achieved a 30-day mortality of roughly 5% and a device success rate of about 93%. One-year mortality dropped from about 27% with first-generation devices to about 9% with dedicated ones.¹⁴ The AURORA trial, which tested one such dedicated device, reported a 91% device-success rate with no deaths during the procedure itself.¹⁵

These are still early days. A large international registry using a mix of device generations reported an overall device-success rate of about 76%, with valve migration occurring in roughly 15% of cases. Patients who experienced migration had a markedly higher rate of death or complications at one year compared with those who did not.¹⁶ For now, transcatheter repair is reserved for patients who genuinely cannot tolerate open surgery, but the technology is improving fast enough that broader use may follow.

The Aorta Itself Can Be a Problem

Aortic regurgitation does not always exist in isolation. In many cases, the same process weakening the valve also affects the aorta. Patients with regurgitation tend to have wider aortas than those with narrowing: in one comparison, the average diameter of the proximal aorta was about 5.2 cm in the regurgitation group versus 4.3 cm in the stenosis group. On tissue analysis, half of the regurgitation patients showed moderate-to-severe breakdown of the elastic fibers in the aortic wall, compared with only 10% of the stenosis patients.¹⁷ This means the risk of aortic dissection or rupture is a real, if uncommon, concern. In some patients, particularly those with bicuspid valves or connective-tissue disorders, the aorta may need to be repaired at the same time as the valve.

Children and Young Adults

Aortic regurgitation in childhood usually stems from a congenital valve abnormality. The management challenges are different from adult disease, because any intervention needs to account for growth. A systematic review and microsimulation study estimated that after aortic valve repair in children (average age around ten), relative life expectancy compared with the matched general population was about 94%. However, the probability of needing a second procedure on the valve within twenty years was roughly 79%.¹⁸

A single-center study spanning thirty years of pediatric aortic valve repair told a consistent story: survival was about 91% at ten years, 87% at twenty, and 84% at thirty. The catch was the high rate of eventual valve replacement, reaching roughly 62% by twenty years and 67% by thirty.¹⁹ For young patients and their families, the practical takeaway is that initial repair can restore near-normal life expectancy, but reoperation is part of the long-term plan rather than a sign that something went wrong.

Pregnancy With a Leaky Aortic Valve

Pregnancy dramatically increases blood volume and cardiac output, which adds to the workload on a heart already dealing with a volume-loaded left ventricle. For most women with mild or moderate aortic regurgitation and preserved heart function, pregnancy is tolerated well. The real risks rise when the regurgitation is severe, when the heart is already dilated, or when the aorta itself is enlarged. Preconception counseling with a cardiologist experienced in pregnancy-related heart disease is important because the hemodynamic stress peaks in the late second and early third trimesters, and decisions about medication, delivery mode, and monitoring intensity need to be made in advance.²⁰ Women with bicuspid valves face the additional concern of aortic enlargement, which may need its own surveillance through pregnancy.

Acute Aortic Regurgitation Is a Different Disease

Everything discussed so far applies to chronic regurgitation, where the leak develops gradually and the heart has time to adapt. Acute aortic regurgitation, caused by events like aortic dissection, endocarditis destroying a valve leaflet, or trauma, is an entirely different clinical scenario. The left ventricle, which has not had time to enlarge and compensate, is suddenly flooded with extra blood. The result is a rapid rise in pressure that backs up into the lungs, causing acute heart failure. Emergency surgery is typically the only option, and without it the condition is frequently fatal within hours to days. The long compensated phase, the gradual monitoring, the careful timing of elective surgery: none of that applies when the leak is sudden.